Skip to content

Omeros OMER Earnings yield

Earnings yield at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-25.7%-6.8pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-7.7%-3.7pp
Immunome logo
ImmunomeIMNM
-9.1%-3.9pp
Vor Biopharma logo
Vor BiopharmaVOR
-733.6%-1,389pp
Annexon logo
AnnexonANNX
-23.8%-9.8pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-13.6%-5.7pp

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Calculated from Omeros’s reported figures.

Based on trailing twelve months.

The official record: Omeros’s 10-Q, filed November 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about Omeros's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's earnings yield?
Omeros (OMER) reported earnings yield of -43.4% in Q3 2025.
How has Omeros's earnings yield changed year-over-year?
Omeros's earnings yield increased by 25.7% year-over-year, from -58.5% to -43.4%.
What is the long-term trend for Omeros's earnings yield?
Over 4 years (2020 to 2024), Omeros's earnings yield has grown at a 15.1% compound annual growth rate (CAGR), from -15.6% to -27.4%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.